Key points are not available for this paper at this time.
Background: In antisynthetase syndrome, anti-Ro52 antibodies appear to be linked to a higher incidence of pulmonary interstitial disease, but not to a worse prognosis. Less data is available on dermatomyositis (DM). Objectives: The aim of this study was to investigate the clinical and prognostic significance of Ro52 positivity in patients with DM. Methods: All patients from a local inflammatory myositis registry (IN.MY.RE.) who fulfilled 2017 ACR/EULAR classification criteria for DM were analyzed. Patients were divided into two groups: DM patients with Ro52 (Ro52+) and DM patients without Ro52 (Ro52-) antibodies. Myositis-specific antibodies (MSA) (Jo1, PL7, PL12, EJ, OJ, Mi2 a/b, TIF1G, MDA5, NXP2, SAE1/2, SRP) were tested using immunodot assay (MYO12D-24, D-Tek, Belgium). Ro52 antibodies were confirmed using ELISA (Enzyme Linked ImmunoSorbent Assay). Patients with antisynthetase syndrome were excluded from the analysis. Results: Eighty-nine patients with DM were included, of whom 15 (16.85%) were Ro52+ and the remaining 74 (83.15%) were Ro52-. No significant differences in clinical characteristics (sex, age, diagnostic delay, DM subset) were found between Ro52+ and Ro52-. Dysphagia was observed more frequently in Ro52- group (13.3% Ro52+ and 51.4% Ro52-, pConclusion: The study findings suggest that Ro52 is most frequently associated with ILD, specifically the DAD subtype, and represent a poor prognostic factor in DM patients. REFERENCES: 1 Anti-Ro52 antibodies positivity in antisynthetase syndrome: a single centre cohort study. Clin Exp Rheumatol. 2022 May;40 Suppl 134(5):27-31. Acknowledgements: NIL. Disclosure of Interests: None declared.
Fornaro et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: